Opko Health (OPK) EBITDA Margin (2010 - 2026)

Opko Health has reported EBITDA Margin for 17 years, with the latest figure at 41.08% in Q1 2026.

• For the quarter ending Q1 2026, EBITDA Margin rose 372.0% year-over-year to 41.08%; the trailing twelve-month figure through Mar 2026 stood at 5.94% (up 4360.0% YoY), and the FY2025 full-year result was 8.35%, up 1297.0% from the prior year.
• EBITDA Margin for Q1 2026 stood at 41.08%, down from 19.13% in the prior quarter.
• The five-year high for EBITDA Margin was 31.68% in Q3 2025, with the low at 1223.76% in Q1 2023.
• Historically, EBITDA Margin has averaged 114.14% across 5 years, with a median of 37.01% in 2023.
• Annual changes were most pronounced in 2022 — EBITDA Margin sank 383146 bps — and 2024, when it jumped 118261 bps.
• Opko Health's EBITDA Margin stood at 29.82% in 2022, then decreased by 27 bps to 37.96% in 2023, then plunged by 634 bps to 278.71% in 2024, then jumped by 107 bps to 19.13% in 2025, then slumped by 315 bps to 41.08% in 2026.
• The last three EBITDA Margin figures came in at 41.08% (Q1 2026), 19.13% (Q4 2025), and 31.68% (Q3 2025), per Business Quant data.